Abstract:Background Oncolytic viruses are promising therapeutic agents for advanced cancers because of their ability to induce antitumor innate and adaptive immunity. Modified vaccinia virus Ankara (MVA) is an attenuated, replication-deficient poxvirus safe for human use, making it a favorable platform for cancer immunotherapy. Previously we discovered the E5R gene in MVA encodes an inhibitor of the cGAS/STING-mediated cytosolic DNA-sensing pathway. The engineered MVA deleting the E5R gene and expressing a dendritic cell (DC) growth factor Flt3L together with a T cell co-stimulator OX40L generates strong antitumor immunity when delivered intratumorally. We also demonstrated that intratumoral (IT) injection of 1st generation rMVA promotes CD8+ activation in a cGAS/STING- and STAT1/STAT2-dependent manner and depletes the OX40hi regulatory T cells (Tregs) via OX40L/OX40 interaction and IFNAR signaling. The E3L gene from MVA encodes an inhibitor of the cytosolic dsRNA-sensing pathways. The purpose of this study is to investigate whether rMVAΔE3L, with the deletion of E3L from rMVA (MVAΔE5R-hFlt3L-mOX40L), further improves its antitumor effects. We also focused on utilizing single-cell RNA-seq (scRNA-seq) to investigate the alteration of the immunosuppressive tumor microenvironment by IT delivery of rMVAΔE3L. Methods We engineered rMVAΔE3L by deleting the E3L gene from rMVA. We investigated the innate immune responses of bone marrow-derived DCs (BMDCs) and tumor cell lines to rMVAΔE3L and rMVA. We also compared the antitumor efficacy of the two viruses in murine B16-F10 melanoma and MC38 colon cancer models. In addition, we performed scRNA-seq of sorted tumor-infiltrating CD45+ immune cells from tumors harvested two days after IT injection with rMVAΔE3L or PBS in wild-type, MDA5/STING-, STAT2-, or IFNAR1-deficient mice. Results Compared with rMVA, rMVAΔE3L more potently activates both the cGAS/STING- and MDA5/MAVS-mediated nucleic acid-sensing pathways in DCs and tumor cell lines. IT rMVAΔE3L generates stronger antitumor effects than rMVA. Our results showed that after rMVAΔE3L treatment, there was an influx of inflammatory monocytes into the tumors in WT mice, absent in STAT2 or IFNAR knockout mice. Evaluation of viral transcriptomes at a single-cell level revealed that macrophages and monocytes were more susceptible to rMVAΔE3L than other cell types. The transcriptomic changes on DC subsets are largely dependent on IFNAR/STAT2 signaling. By contrast, MDA5/STING-mediated pathway determines the transcriptome profile of inflammatory monocytes in response to rMVAΔE3L. Conclusions Taken together, our results demonstrate that scRNA-seq is a powerful approach to interrogate the host immune responses to immunogenic viruses, which would guide future designs of more effective viral-based cancer immunotherapy. Acknowledgements This work was supported that the Society of Memorial Sloan Kettering (MSK) research grant (L.D.), MSK Technology Development Fund (L.D.), Parker Institute for Cancer Immunotherapy Career Development Award (L.D.), sponsored research award from IMVAQ Therapeutics. This work was supported in part by the Swim across America (J.D.W., T.M.), Ludwig Institute for Cancer Research (J.D.W., T.M.), National Cancer Institute grants R01 CA56821 (J.D.W). This research was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Intratumoral delivery of engineered recombinant modified vaccinia virus Ankara expressing Flt3L and OX40L generates potent antitumor immunity through activating the cGAS/STING pathway and depleting tumor-infiltrating regulatory T cells

OX40L-expressing Recombinant Modified Vaccinia Virus Ankara Induces Potent Antitumor Immunity Via Reprogramming Tregs

SINGLE-CELL RNA-SEQ REVEALS THE CRITICAL ROLES OF THE STING- AND MDA5-MEDIATED CYTOSOLIC NUCLEIC ACID-SENSING PATHWAYS AS WELL AS IFNAR/STAT2 SIGNALING IN RECOMBINANT MVA-INDUCED ANTITUMOR IMMUNITY

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

IL-12-expressing highly immunogenic recombinant modified vaccinia virus Ankara reprograms tumor-infiltrating myeloid cells to overcome immune resistance

An Engineered Oncolytic Vaccinia Virus Encoding a Single-Chain Variable Fragment Against TIGIT Induces Effective Antitumor Immunity and Synergizes with PD-1 or LAG-3 Blockade.

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Enhanced Antitumor Efficacy Of A Novel Oncolytic Vaccinia Virus Encoding A Fully Monoclonal Antibody Against T-Cell Immunoglobulin And Itim Domain (Tigit)

Intratumoral Administration of Immature Dendritic Cells Following the Adenovirus Vector Encoding CD40 Ligand Elicits Significant Regression of Established Myeloma

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

A Bi-Adjuvant Nanovaccine Amplifying STING Activation for Cancer Immunotherapy

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

Intratumoral Delivery Of A Pd-1-Blocking Scfv Encoded In Oncolytic Hsv-1 Promotes Antitumor Immunity And Synergizes With Tigit Blockade

CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging

Abstract 3542: Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy

Intravenous Injection of the Oncolytic Virus M1 Awakens Antitumor T Cells and Overcomes Resistance to Checkpoint Blockade

Abstract 1718: Tumor Eradicated by an Effective in Situ Vaccine Based on a TLR Agonist and an Agonistic Anti-Ox40 Antibody

Oncolytic Adenovirus-Mediated Intratumoral Expression of TRAIL and CD40L Enhances Immunotherapy by Modulating the Tumor Microenvironment in Immunocompetent Mouse Models.

Activation of Human Dendritic Cells by Recombinant Modified Vaccinia Virus Ankara Vectors Encoding Survivin and IL-2 GenesIn Vitro